Depymed Announces Validation Of Trodusquemine As A Therapeutic Candidate For HER2-Positive Breast Cancer
5/27/2014 9:25:02 AM
NEW YORK, May 27, 2014 (GLOBE NEWSWIRE) -- DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) and Cold Spring Harbor Laboratory, today announced the validation of Trodusquemine (MSI-1436) as a therapeutic candidate for HER2-positive breast cancer. Trodusquemine is the Company's inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). The results were published online on May 20, 2014 in Nature Chemical Biology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by